Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Nootropic drug evaluation for general practice]

R Ihl1, C Kretschmar

  • 1Rheinische Kliniken, Heinrich-Heine-Universität, Düsseldorf.

Der Nervenarzt
|September 11, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current Situation of Paediatric and Adult Patients With Fragile X Syndrome: Preliminary Data From the Explain Fxs Registry.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2012
Same author

Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial.

Pharmacopsychiatry·2011
Same author

Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761®) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial.

Journal of the neurological sciences·2010
Same author

[Challenging pharmacotherapy in dementia].

MMW Fortschritte der Medizin·2009
Same author

World psychiatric association section of old age psychiatry consensus statement on ethics and capacity in older people with mental disorders.

International journal of geriatric psychiatry·2009
Same journal

[When brain abscesses run in the family…].

Der Nervenarzt·2026
Same journal

[Digital health applications and adherence in depression: a qualitative study from the perspective of healthcare providers].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

[Rare genetic diseases with frequent mental symptoms].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
See all related articles

Nootropic drugs may help improve dementia symptoms and slow disease progression with few side effects. Combining nootropics with environmental and training interventions offers economic benefits and enhances treatment efficacy.

Area of Science:

  • Gerontology
  • Pharmacology
  • Neurology

Context:

  • Dementia treatment is often empirical.
  • Nootropic drugs are frequently used.
  • Need for evidence-based treatment strategies.

Purpose:

  • Evaluate the efficacy of nootropic drugs for dementia.
  • Assess side effects and economic aspects.
  • Compare nootropics with alternative treatments.

Summary:

  • Literature review indicates nootropics improve early dementia symptoms and delay disease progression.
  • Most nootropic substances have minimal severe side effects.
  • Further research needed on comparative and prophylactic effects.

Impact:

Related Experiment Videos

  • Nootropic treatment combined with environmental and training interventions yields better results.
  • Economic analysis suggests nootropics are cost-effective, particularly by delaying care unit admission.
  • Proposal for rational nootropic treatment derived from data.